RadNet (RDNT) Q4 2025: Digital Health ARR Set to Surge 86% with Gleamer Acquisition
RadNet’s Q4 marked an inflection in digital health scale, with the Gleamer deal positioning it as the global leader in radiology clinical AI. Advanced imaging mix and joint venture expansion drove record imaging results, while the company’s focus on SaaS recurring revenue is reshaping its margin and cash flow profile. Guidance signals further acceleration in both imaging and digital health, underpinned by operational leverage and AI-driven efficiency gains.
Summary
- AI Platform Scale-Up: Gleamer integration cements RadNet as the largest clinical radiology AI provider globally.
- Advanced Imaging Drives Margin: Shift toward high-acuity modalities boosts profitability and operational leverage.
- Recurring Revenue Focus: Digital health ARR nearly doubles, setting the stage for margin expansion and global reach.
Business Overview
RadNet operates the largest network of outpatient diagnostic imaging centers in the United States, generating revenue through imaging procedures (MRI, CT, PET/CT, X-ray, mammography) and digital health solutions. The business is structured around two primary segments: Imaging Centers, which drive procedural revenue, and Digital Health, a fast-growing SaaS and AI-powered workflow platform that serves both RadNet’s own centers and third-party providers globally.
Performance Analysis
Q4 2025 delivered record revenue and adjusted EBITDA, driven by strong volume growth in advanced imaging and a surging digital health segment. Imaging centers saw aggregate procedural volume up 14.1% and same-center advanced imaging up 9.6% year-over-year, with advanced modalities now representing over 28% of total volume. This higher-acuity mix, led by MRI, CT, and PET/CT, is crucial—these account for more than 60% of total company revenue and are the primary margin drivers.
Digital Health revenue jumped 48% year-over-year, with adjusted EBITDA up nearly 9%. The segment’s growth was partially fueled by the ICAD acquisition, but even excluding this, organic expansion remained robust. Notably, RadNet’s recurring revenue base is transforming: the newly introduced annual recurring revenue (ARR) metric for digital health reached $75 million at year-end, with 2026 guidance targeting nearly $140 million, reflecting both organic momentum and the transformative Gleamer deal.
- Advanced Imaging Mix Shift: 178 basis point increase in advanced imaging share, boosting revenue per procedure and margin.
- Digital Health Momentum: ARR set to grow by over $65 million in 2026, driven by SaaS adoption and global expansion.
- Operational Leverage: Free cash flow guided to rise 29–41% in 2026 as margin expansion outpaces cost inflation.
Liquidity remains strong with $767 million cash at year-end and net leverage at approximately 1x, giving RadNet ample firepower for further acquisitions and growth investments.
Executive Commentary
"The acquisition of Gleamer is a transformative milestone for us. It establishes DeepHealth as the largest provider of radiology clinical AI solutions worldwide, expands its global footprint, strengthens operational performance across high-volume workflows, and accelerates the delivery of AI-enabled automated diagnostics."
Case Westorp, President and CEO of Digital Health
"Radiology is entering a new era... The opportunity for RADNET now expands well beyond the outpatient centers and into relationships that we expect to grow deeper with hospitals and hospital systems... We now stand on the precipice of major transformative changes."
Dr. Howard Berger, President and CEO
Strategic Positioning
1. Digital Health Platform Leadership
The Gleamer acquisition vaults RadNet’s DeepHealth to the top of the global radiology AI market, with a combined portfolio spanning 26 FDA-cleared and 22 CE-marked solutions across all major modalities. Gleamer’s cloud-native, SaaS-first model and strong recurring revenue base accelerate DeepHealth’s ARR growth and global reach, especially in Europe and EMEA.
2. Advanced Imaging Margin Engine
RadNet’s capital investments in high-acuity imaging (MRI, CT, PET/CT) and AI-driven scheduling (TechLive) are shifting its revenue mix toward higher-margin modalities. This dynamic is central to margin expansion and operational leverage, as advanced imaging now represents an increasing share of both volume and profit.
3. Health System Joint Ventures and De Novo Expansion
RadNet’s health system partnerships now account for over 36% of its 418 centers, with joint ventures driving procedural volume through access to hospital physician networks. The company is also expanding via new builds and acquisitions in growth markets like Florida and Indiana, supporting both organic and inorganic revenue growth.
4. SaaS Recurring Revenue Transformation
The introduction and rapid scaling of ARR as a key metric signals a strategic pivot to a SaaS-based, subscription-driven business model. The digital health segment’s revenue mix is shifting from implementation and hardware to recurring software and support, driving predictability, margin, and valuation uplift.
5. AI-Driven Efficiency and Labor Leverage
AI-powered workflow automation is targeting both clinical and operational bottlenecks, with draft reporting and automated triage expected to deliver measurable productivity gains starting in Q3 2026. This is especially critical given persistent industry-wide labor shortages among radiologists and technologists.
Key Considerations
RadNet’s Q4 and full-year performance underscore a business model in transition, with the digital health segment and advanced imaging mix driving both growth and margin expansion. The company’s capital allocation and partnership strategy are positioning it to capture share from hospital-based imaging as payers and patients seek lower-cost, high-quality alternatives.
Key Considerations:
- AI Commercialization Acceleration: Cross-selling and upselling opportunities across a 2,700+ global customer base, with 80–90% of contracts offering incremental wallet share potential.
- Recurring Revenue Quality: Digital Health’s ARR is on track to surpass $140 million by year-end, with SaaS penetration driving predictable, high-margin growth.
- Operational Efficiency Upside: AI-enabled draft reporting and triage expected to unlock radiologist capacity and reduce cost per procedure, particularly in high-volume X-ray and lumbar MRI workflows.
- JV and De Novo Pipeline Depth: Inbound interest from health systems is at an all-time high, with larger-scale JV opportunities and new center builds in receptive markets underpinning forward growth.
- Leverage and Cash Flexibility: Net leverage remains conservative (1.6–1.8x pro forma for acquisitions), preserving capacity for further M&A and internal investment.
Risks
Execution risk remains elevated as RadNet integrates multiple acquisitions and ramps new AI solutions, with EBITDA drag from Gleamer ($5 million loss expected in 2026) and ongoing investments in sales, service, and regulatory capacity. Labor cost inflation (guided at 4% same-center growth) and weather-related volume disruptions are embedded in near-term guidance. Competitive dynamics in radiology AI, especially from hospital-focused IT incumbents, could pressure pricing or slow adoption if integration or cross-selling lags expectations.
Forward Outlook
For Q1 2026, RadNet expects:
- Imaging center revenue growth despite winter weather headwinds
- Digital health ARR and SaaS revenue ramping as new contracts activate
For full-year 2026, management guided to:
- Imaging center revenue growth of 17–19% (including $120 million from recent acquisitions)
- Digital health revenue growth of 45–55%
- ARR approaching $140 million by year-end
- Free cash flow up 29–41% over 2025
Management emphasized margin expansion from both segments, with digital health EBITDA expected to inflect as cost synergies from Gleamer and ICAD are realized and as recurring revenue scales. Four FDA clearances are targeted for 2026, further expanding the clinical AI portfolio.
- ARR growth driven by SaaS adoption and Gleamer integration
- Potential new JV announcements with large health systems
Takeaways
RadNet’s Q4 2025 marks a pivotal step in its evolution from a pure-play imaging operator to a global clinical AI platform leader.
- Margin and Growth Engine: Advanced imaging and SaaS digital health are now the core drivers of profitability, with recurring revenue quality and operational leverage set to rise.
- Integration and Execution Watch: The Gleamer and ICAD integrations, combined with new market entries, will test management’s ability to sustain both top-line and margin momentum.
- Strategic Optionality: Investors should monitor the pace of digital health cross-sell, JV expansion, and AI-driven efficiency gains as leading indicators of long-term value creation.
Conclusion
RadNet’s Q4 results and 2026 outlook highlight a business in transformation, with the Gleamer acquisition and ARR growth providing both scale and visibility. The next phase will hinge on successful integration and the realization of AI-driven productivity gains, setting a new standard for radiology delivery and digital health monetization.
Industry Read-Through
RadNet’s aggressive pivot to SaaS and clinical AI is a bellwether for outpatient imaging and healthcare IT. Its ability to integrate workflow automation, advanced imaging, and global commercial reach signals rising barriers to entry and a shift in competitive dynamics. Incumbent imaging IT vendors and hospital-based radiology groups face mounting pressure to match RadNet’s portfolio breadth and operational efficiency. The push toward recurring revenue and AI-enabled productivity is likely to accelerate industry consolidation and increase the strategic value of digital health assets across healthcare services.